Is hepcidin a new cardiovascular risk marker in polycystic ovary syndrome?

Gynecologic and Obstetric Investigation

Volumn 75, Issue 3, 2013, Pages 196-202

  Gözdemir, Elif ^a   Kaygusuz, Ikbal ^b   Kafali, Hasan ^b  

^a Sungurlu Hospital   (Turkey)

^b TURGUT OZAL UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Hepcidin; Insulin resistance; Obesity; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; FOLLITROPIN; HEMOGLOBIN; HEPCIDIN; INSULIN; INTERLEUKIN 6; IRON; LUTEINIZING HORMONE; TRANSFERRIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRON BINDING CAPACITY; LUTEINIZING HORMONE BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL; AGE; DISEASE COURSE; IRON METABOLISM; PREDICTION; PROSPECTIVE STUDY;

ADULT; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; IRON; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; YOUNG ADULT;

EID: 84876794070     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000348497     Document Type: Article

References (34)

1. Seow KM, Juan CC, Wang P.H., Ho LT, Hwang JL: Expression levels of vascular cell adhesion molecule-1 in young and nonobese women with polycystic ovary syndrome. Gynecol Obstet Invest 2012; 73:236-241.
2. Siebert TI, Viola MI, Steyn D.W., Kruger TF: Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol Obstet Invest 2012; 73:304-313.
3. Vrbikova J, Fanta M, Cibula D., Vondra K, Bendlova B: Impaired glucose metabolism in women with polycystic ovary syndrome. Gynecol Obstet Invest 2009; 68:186-190.
4. Shroff R, Kerchner A, Maifeld M., Van Beek EJ, Jagasia D, Dokras A: Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92:4609-4614. (Pubitemid 350223434)
5. Blake GJ, Ridker PM: Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002; 252:283-294. (Pubitemid 35253696)
6. Nakanishi T, Hasuike Y, Otaki Y Kida A, Nonoguchi H, Kuragano T: Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant 2011; 26:3092-3100.
7. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783-788. (Pubitemid 36917762)
8. Park CH, Valore EV, Waring A.J., Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
9. Bekri S, Gual P, Anty R., Luciani N, Dahman M, Ramesh B., Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, Saint-Paul MC, Huet P.M., Sadoul JL, Gugenheim J, Srai SK, Tran A, Le Marchand-Brustel Y: Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131:788-796. (Pubitemid 44316823)
10. Nemeth E, Valore EV, Territo M, Schiller G., Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461-2463. (Pubitemid 36857598)
11. Fleming MD: The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008; 151-158.
12. Kuragano T, Itoh K, Shimonaka Y Kida A, Furuta M, Kitamura R, Yahiro M, Nanami M, Otaki Y, Hasuike Y, Nonoguchi H, Nakanishi T: Hepcidin as well as TNF alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011; 26:2663-2667.
13. Valenti L, Dongiovanni P, Motta B.M., Swinkels DW, Bonara P, Rametta R, Burdick L., Frugoni C, Fracanzani AL, Fargion S: Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011; 31:683-690.
14. Sullivan JL: Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007; 232:1014-1020. (Pubitemid 47358184)
15. Luque-Ramírez M, A & Acute;lvarez-Blasco F, Alpañés M, Escobar-Morreale HF: Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:846-852.
16. Nicolas G, Bennoun M, Porteu A., Mativet S, Beaumont C, Grandchamp B., Sirito M, Sawadogo M, Kahn A., Vaulont S: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99:4596-4601. (Pubitemid 34286030)
17. Roetto A, Papanikolaou G, Politou M., Alberti F, Girelli D, Christakis J., Loukopoulos D, Camaschella C: Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33:21-22. (Pubitemid 36068676)
18. Escobar-Morreale H.F., Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sancho J, San Millán JL: Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2005; 28: 2042-2044. (Pubitemid 41060986)
19. Luque-Ramírez M, Alvarez-Blasco F, BotellaCarretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF: Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007; 30:2309-2313. (Pubitemid 47359039)
20. Le Guenno G., Chanseaume E, Ruivard M., Morio B, Mazur A: Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Pract 2007; 77: 363-370. (Pubitemid 47211345)
21. Sanad M, Osman M, Gharib A: Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: a case control study. Ital J Pediatr 2011; 37:34.
22. Wenzel BJ, Stults HB, Mayer J: Hypoferraemia in obese adolescents. Lancet 1962; 2:327-328.
23. Pinhas-Hamiel O., Newfield RS, Koren I, Agmon A., Lilos P, Phillip M: Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes Relat Metab Disord 2003; 27:416-418. (Pubitemid 36384882)
24. Greenberg AS, Obin MS: Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83:461-465.
25. Escobar-Morreale H.F., Villuendas G, BotellaCarretero J.I., Sancho J., San Millán JL: Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003; 46:625-633. (Pubitemid 36808182)
26. Möhlig M., Spranger J, Osterhoff M., Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G., Schöfl C: The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150:525-532. (Pubitemid 38584704)
27. Orio F Jr, Palomba S., Cascella T, Di Biase S, Manguso F: The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:2-5. (Pubitemid 40116624)
28. Chiu KM, Arnaud CD, Ju J, Mayes D., Bacchetti P, Weitz S, Keller ET: Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle. Bone 2000; 26:79-85.
29. Kelly CC, Lyall H, Petrie J.R., Gould GW, Connell JM, Sattar N: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-2455. (Pubitemid 32545690)
30. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T., Duman C: Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89:5592-5596. (Pubitemid 39518445)
31. Diamanti-Kandarakis E., Paterakis T, Alexandraki K., Piperi C, Aessopos A, Katsikis I., Katsilambros N, Kreatsas G, Panidis D: Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426-1431. (Pubitemid 44445017)
32. Rajapurkar MM, Shah SV, Lele S.S., Hegde UN, Lensing SY, Gohel K, Mukhopadhyay B., Gang S, Eigenbrodt ML: Association of catalytic iron with cardiovascular disease. Am J Cardiol 2012; 109:438-442.
33. Saeed O, Otsuka F, Polavarapu R., Karmali V, Weiss D, Davis T., Rostad B, Pachura K, Adams L., Elliott J, Taylor WR, Narula J, Kolodgie F., Virmani R, Hong CC, Finn AV: Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:299-307.
34. Finn AV, Nakano M, Polavarapu R Karmali V, Saeed O, Zhao X, Yazdani S, Otsuka F, Davis T, Habib A, Narula J, Kolodgie FD, Virmani R: Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol 2012; 59:166-177.